Literature DB >> 11722319

Familial occurrence of tardive dyskinesia.

D J Müller1, T G Schulze, M Knapp, T Held, H Krauss, T Weber, G Ahle, A Maroldt, D Alfter, W Maier, M M Nöthen, M Rietschel.   

Abstract

OBJECTIVE: Familial occurrence of tardive dyskinesia (TD) and schizophrenia has been hypothesized to confer risk to the development of TD. We investigated these hypotheses in a large patient sample applying standardized methods for phenotype characterization.
METHOD: Two hundred and twenty-two patients with a diagnosis of schizophrenia or schizoaffective disorder were assessed for TD and for family history of schizophrenia or schizoaffective disorder. Thirty-nine patients had 40 affected first-degree family members, one patient having two first-degree relatives. Of these, 17 pairs and one triplet were personally examined.
RESULTS: 1) There was a tendency for TD in the affected relatives to be associated with the TD status of the index-patient; this finding was unrelated to age and doses of neuroleptic medication. 2) No association between a family history of schizophrenia or schizoaffective disorder and TD was found.
CONCLUSION: A family history of TD might represent a risk factor for TD, whereas a family history of schizophrenia does not.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11722319     DOI: 10.1034/j.1600-0447.2001.00401.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  23 in total

1.  Pharmacogenetics of antipsychotic treatment response and side effects.

Authors:  B Mackenzie; Rp Souza; O Likhodi; Ak Tiwari; Cc Zai; J Sturgess; Dj Müller
Journal:  Therapy       Date:  2010-03

Review 2.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

Review 3.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

4.  Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.

Authors:  Li Hui; Mei Han; Xu Feng Huang; Min Jie Ye; Ke Zheng; Jin Cai He; Meng Han Lv; Bao Hua Zhang; Jair C Soares; Xiang Yang Zhang
Journal:  J Neural Transm (Vienna)       Date:  2014-10-22       Impact factor: 3.575

Review 5.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 6.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 7.  Genetics of Common Antipsychotic-Induced Adverse Effects.

Authors:  Raymond R MacNeil; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2016-05-20

Review 8.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

9.  Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice.

Authors:  James J Crowley; Yunjung Kim; Jin Peng Szatkiewicz; Amanda L Pratt; Corey R Quackenbush; Daniel E Adkins; Edwin van den Oord; Molly A Bogue; Hyuna Yang; Wei Wang; David W Threadgill; Fernando Pardo-Manuel de Villena; Howard L McLeod; Patrick F Sullivan
Journal:  Mamm Genome       Date:  2011-12-30       Impact factor: 2.957

Review 10.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.